About

For more than twenty years, I worked inside global capital markets. At Credit Suisse (later UBS), I advised ultra-high-net worth families, constructed portfolios, and helped investors navigate uncertainty. In that role, I oversaw approximately $5 billion in client assets and more than $700 million in advisory mandates.

Over time, a pattern became impossible to ignore. Entire areas of healthcare affecting half the population were almost invisible to capital because the system wasn’t designed to see it.

Women’s health is one of those gaps, and today healthcare stands at an inflection point. Across diagnostics, therapeutics, and longevity science, a new frontier of healthcare innovation is emerging that markets are only beginning to understand.

Today my work focuses on helping sophisticated investors access structural opportunities emerging across women’s health, precision medicine, and healthcare innovation through an institutional capital markets lens.

This is not values-based investing detached from returns. It is a structural investment thesis grounded in demographic shifts, scientific progress, and capital market inefficiencies.